Skip to main content

G2 Acquires Lophos Pharma, a peyote focused psychedelics company 

Written by Customer Service on . Posted in Mergers And Acquisitions.

TORONTO, Jan. 21, 2022 (GLOBE NEWSWIRE) — Greenridez 2.0 Acquisitions Corp. (the “Company“) is pleased to announce that it has completed its acquisition of psychedelic research company Lophos Pharma (“Lophos”).

Lophos Pharma is a psychedelic research company primarily focused on novel therapeutic treatments derived from Peyote (Lophophora williamsii). The Company strongly supports Lophos Pharma’s belief in Peyote’s potential to treat indications ranging from weight loss and addiction, to anxiety and depression. Greenridez 2.0 Acquisitions Corp. will be operating as Lophos Holdings going forward and has appointed Claire Stawnyczy as Chief Executive Officer.

Claire gained substantial pharmaceutical experience from her work in the biotechnology industry before transferring to cannabis in 2017. During Claire’s time as CEO of Canalytica Corp., a business management and regulatory consulting firm, she led numerous Licensed Producers in achieving regulatory compliance and streamlining business operations. Claire’s experience, drive and respect for the Peyote plant and its history not only make her uniquely qualified to lead the Lophos team, but to be an excellent ambassador for this important and nascent segment of the psychedelics market.

“I look forward to leading the Lophos team and respectfully adding to Peyote’s proud history,” said Claire Stawnyczy, CEO of Lophos. “We are excited by Health Canada’s recent amendment to the special access program and look forward to supplying patients in the future.”

About Lophos Pharma

Lophos is a biosciences company that specializes in Peyote research, cultivation, preservation, and drug development. We develop novel therapies and natural health treatments that aim to restore and improve the quality of life for patients. Through advanced cultivation and harvesting techniques, Lophos Pharma will provide our partners with medical grade inputs and our patients with access to safe and effective mescaline-based therapeutics. 

Contact
Claire Stawnyczy, CEO
Claire@lophos.com

Forward Looking Statements

Except for statements of historical fact, this news release contains certain “forward-looking information” within the meaning of applicable Canadian securities legislation. These statements relate to future events or future performance. The use of any of the words “could”, “intend”, “expect”, “believe”, “will”, “projected”, “estimated” and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on the Company’s current belief or assumptions as to the outcome and timing of such future events. Forward looking information in this news release includes information with respect to the Company’s drug development programs. Forward-looking information is based on reasonable assumptions that have been made by the Company at the date of the information and is subject to known and unknown risks, uncertainties, and other factors that may cause actual results or events to differ materially from those anticipated in the forward-looking information. Given these risks, uncertainties and assumptions, you should not unduly rely on these forward-looking statements. The forward-looking information contained in this news release is made as of the date hereof, and the Company is not obliged to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. The foregoing statements expressly qualify any forward-looking information contained herein.

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.